Last reviewed · How we verify
Ilaris®
Ilaris (canakinumab) is a monoclonal antibody that blocks interleukin-1 beta (IL-1β), a key inflammatory cytokine, to reduce inflammation and its downstream effects.
Ilaris (canakinumab) is a monoclonal antibody that blocks interleukin-1 beta (IL-1β), a key inflammatory cytokine, to reduce inflammation and its downstream effects. Used for Cryopyrin-associated periodic syndromes (CAPS), Systemic juvenile idiopathic arthritis (sJIA), Acute coronary syndrome (ACS) with elevated inflammatory markers.
At a glance
| Generic name | Ilaris® |
|---|---|
| Also known as | canakinumab |
| Sponsor | AO GENERIUM |
| Drug class | IL-1β inhibitor (monoclonal antibody) |
| Target | IL-1β (Interleukin-1 beta) |
| Modality | Biologic |
| Therapeutic area | Immunology / Rheumatology / Rare Inflammatory Diseases |
| Phase | FDA-approved |
Mechanism of action
Canakinumab selectively binds to and neutralizes IL-1β, preventing its interaction with IL-1 receptors on immune and tissue cells. This inhibition reduces the production of downstream inflammatory mediators and the recruitment of inflammatory cells, thereby suppressing systemic inflammation in conditions driven by IL-1β overproduction.
Approved indications
- Cryopyrin-associated periodic syndromes (CAPS)
- Systemic juvenile idiopathic arthritis (sJIA)
- Acute coronary syndrome (ACS) with elevated inflammatory markers
- Gout (acute flares and prophylaxis)
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis (PHASE2)
- Ilaris NIS in Korea
- An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease (PHASE3)
- Canakinumab for the Treatment of Postprandial Hypoglycemia (PHASE3)
- A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers (PHASE1)
- Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy (PHASE1, PHASE2)
- Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |